Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-664 in Treatment-Naïve Primary Immunodeficiency Diseases
NCT07794735Phase 4Not yet recruiting
- Sponsor
- Takeda
- Start
- Nov 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 4 trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID), sponsored by Takeda. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT07794735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07794735.